Engflag

Kelual DS

Quick links to important sections

Kelual DS

Kelual DS_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kelual DS

Property Description
Active Ingredients Ciclopirox, Piroctone Olamine, Crotamiton, Glycolic Acid
Form Topical Preparation (Shampoo, Cream, or Emulsion)
Pharmacological Class Multifactorial Antiseborrheic (Antifungal, Keratolytic, Antipruritic)
Common Use Management of persistent scaling, flaking, and itching
Origin Combination of Synthetic and Naturally-derived Components

Defining the Kelual DS Topical Preparation

Kelual DS is a multifactorial antiseborrheic topical preparation designed for cutaneous application, primarily utilized for the management of scaling and intense flaking associated with seborrheic conditions. The product is categorized as a dermo-cosmetic, positioning it to deliver ingredients with recognized therapeutic efficacy directly to the skin or scalp. As a complex combination product, its integrated pharmacological class involves simultaneous antifungal, keratolytic, and antipruritic actions. The preparation is most commonly known in its shampoo dosage form, though cream or emulsion variants may also be available for targeted application.

Comprehensive Composition and Synergistic Active Ingredients

The preparation's efficacy is derived from the synergistic inclusion of several active ingredients, which pairs synthetic broad-spectrum antifungals with exfoliating and soothing agents. The core antifungal component, Ciclopirox, is clinically recognized for its action against Malassezia species yeasts, a biological agent linked to seborrheic flare-ups. This synthetic agent is complemented by Piroctone Olamine and the keratolytic compounds Glycolic Acid and Guanidine Carbonate, which promote the removal of scales. The formulation's distinctive multi-component strategy integrates Crotamiton to immediately address irritation and the botanical extract Saw Palmetto, contributing to its unique anti-irritation profile.

General Purpose: Management of Seborrheic Scaling and Pruritus

The general therapeutic purpose of Kelual DS is the comprehensive management of persistent symptoms, including intense flaking, scaling, and the uncomfortable pruritus (itching) that often characterizes seborrheic dermatitis. By combining agents that control the underlying yeast overgrowth with those that promote the efficient shedding of dead skin cells, the product is specifically designed to manage the two primary observable symptoms. This multi-target approach is supported by guidance recommending multi-component topical therapy for difficult-to-treat scalp conditions, ensuring sustained relief from chronic scaling and inflammation.

What side effects are possible with Kelual DS?

Possible Side Effects and Safety Information

The officially documented safety profile for topical preparations containing Ciclopirox and Crotamiton is primarily focused on local application site reactions and is structured by governmental regulatory agencies.

Adverse Reaction Scope

Adverse effects are mainly classified under Skin and Subcutaneous Tissue Disorders and Hair and Follicle Disorders. The most frequently reported adverse reactions, classified as Common in regulatory documents, include local pruritus (itching), a burning sensation, and erythema (redness) at the application site. The label for Crotamiton topical notes skin irritation or rash as a rare occurrence. Postmarketing reports for Ciclopirox shampoo also document changes to the hair, such as hair discoloration and abnormal hair texture, although their frequency is not established.

Regulatory Safety Considerations

The most significant safety constraint is the official contraindication for individuals with a known hypersensitivity to any component of the preparation. This type of topical therapy is also officially not for ophthalmic use and should not be applied to areas with acutely inflamed, raw, or weeping skin. Safety and effectiveness have not been established in pediatric patients below specific age limits according to various regulatory labels. Regarding pregnancy, Ciclopirox is typically classified under Pregnancy Category B, while Crotamiton is assigned Category C, meaning use during pregnancy should only occur if the potential benefit justifies the potential risk, as defined by the regulatory documents. The appearance of signs of increased irritation may be indicative of possible sensitization.

Overdose and Emergency Response

The official regulatory documents detailing the overdose profile for this topical preparation differentiate between local over-application and accidental oral ingestion. Over-application to the skin may result in documented manifestations of increased local irritation or signs consistent with possible sensitization. These reactions can include intensified redness, burning, itching, or swelling at the application site.

For such acute localized presentations, the regulatory instructions specify that treatment must be discontinued, and appropriate supportive therapy should be instituted to manage the symptoms.

However, the primary severe exposure scenario addressed by regulatory authorities is the accidental oral ingestion of the product, as it is strictly labeled for external topical use. In the event that this preparation is swallowed, the official guidance mandates that an individual seek immediate medical attention or contact a Poison Control Center right away.

Management of ingestion is defined as symptomatic and supportive, particularly because no specific antidote is known for the active ingredients within the formulation. Given the documented risk of accidental ingestion, regulatory labeling includes a specific precaution that the product must be kept out of the reach of children.

Therapeutic Uses of Kelual DS

Kelual DS may be part of symptomatic management across therapeutic domains where additional symptomatic support is needed for conditions involving recurrent or episodic manifestations. It is relevant in contexts marked by increased discomfort or tension and is applied in addressing certain distressing symptoms associated with seborrheic dermatitis. This type of therapy is used for seborrheic dermatitis of the scalp.

This therapeutic domain is commonly used to help with symptom clusters related to physical discomfort stemming from scaling and flaking, pruritus (itching), and associated redness. The preparation plays a role in managing these visible manifestations, assisting patients by contributing to easing the overall symptom load. It is relevant for easing symptom clusters in conditions involving recurrent or episodic manifestations. It may be part of symptomatic management when symptoms may intensify temporarily.

“The primary goal of this therapy is to address visible scaling and provide support that helps ease the overall symptom burden.”

Quick Fact: Symptomatic Support for Pruritus and Recurrence The application provides support that helps maintain a sense of stability during and between episodes of heightened discomfort. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH DailyMed Ciclopirox Shampoo Label

Eligibility and Restrictions for Use

Kelual DS treatment shampoo is generally indicated for individuals experiencing severe or recurrent dandruff conditions that are often associated with intense itching and redness, or as an accompanying treatment for the scalp in cases of seborrheic dermatitis.

It is suitable for adults and adolescents.

Contraindications and Specific Populations

Population Usage Consideration
Children Not generally recommended for children under the age of 14 due to lack of extensive data. Consult a pediatrician or dermatologist before use.
Pregnancy While topical use of its active ingredients typically results in minimal systemic absorption, general caution is advised. Consult a healthcare provider before use if pregnant or planning to become pregnant.
Breastfeeding As a precautionary measure concerning the active ingredients, consultation with a healthcare professional is recommended before use during breastfeeding.

It is also essential to avoid contact with the eyes; if contact occurs, rinse thoroughly with water. Individuals with known sensitivities or allergies to the active ingredients (such as Ciclopirox Olamine or Piroctone Olamine) or any other component of the formulation should not use this product.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this topical preparation is structured around the very low potential for systemic drug interactions, which is characteristic of minimal dermal absorption. All documented constraints relate to formal prohibitions and specific co-administration restrictions found in official prescribing information.

Interaction Classification and Restrictions

Contraindications

The preparation is formally contraindicated in individuals with a known hypersensitivity to any of its active components (Ciclopirox, Piroctone Olamine, Crotamiton, Glycolic Acid) or to any of its excipients.

Pharmacokinetic Non-Interaction Profile

Due to the minimal systemic absorption of the primary antifungal ingredient, Ciclopirox, which is typically less than five percent of the applied dose, and its metabolism via glucuronidation rather than the cytochrome P450 (CYP450) enzyme system, significant drug interactions with systemic CYP450-metabolized medicines are not anticipated. Furthermore, regulatory documentation confirms that the active ingredient does not share the P-glycoprotein inhibition concerns that are often associated with other antifungal classes.

Co-Administration Restrictions

Official regulatory information states that the concomitant use with systemic antifungal agents is not recommended in certain product labels for topical Ciclopirox. This restriction is based on the lack of clinical data to confirm that the topical preparation does not interfere with the therapeutic efficacy of the systemic agent. No specific interactions with food, alcohol, or herbal products are formally documented in the official prescribing information.

Mechanism of Action

Modulating Microbial Activity and Growth

The product functions as a fungistatic agent, delivering components like Ciclopirox Olamine and Piroctone Olamine to the skin's surface. These agents directly disrupt the cell metabolism and membrane integrity of Malassezia yeasts, primarily by chelating polyvalent metal cations, such as Fe^3+ . This action inhibits metal-dependent enzymes, thereby controlling the yeast population density and decreasing the concentration of microbial mediators that initiate local biological responses.

Attenuating Inflammatory Pathways

The mechanism also includes the modulation of local signaling cascades within the tissue. Active components interfere with the arachidonic acid cascade by inhibiting enzymes like cyclooxygenase and 5-lipoxygenase. This action induces the dampening of physiological processes that cause localized vascular changes and immune cell activation, contributing to a reduction in localized cellular hyperactivity.

Facilitating Epidermal Cell Detachment

A separate mechanistic domain involves keratolysis, where certain ingredients act on the outermost layer of the skin ( stratum corneum) to facilitate the breakdown of adhesive bonds ( desmosomes) between aggregated, dead cells. This promotes the separation and shedding of aggregated cells, which produces a reduction in the accumulation of superficial cellular material and modifies the superficial barrier structure.

Dosage and Administration Information

How to Use Kelual DS

The usage of Kelual DS is defined by a structured, two-phase regimen designed for topical administration to the affected scalp or skin areas. The regimen is split between an initial period of high-frequency application and a subsequent long-term maintenance schedule, consistent with the protocols for its primary active component, Ciclopirox Shampoo 1%.

Administration Scope and Scheduling

Feature Detail
Route of administration Topical application only (External use).
Dosing schedule Initial Phase: Two to three times per week. Maintenance Phase: Once per week.
Age-group rules Authorized for use in Adults and Adolescents (ge 16 years).
Duration The initial attack phase typically lasts two to four weeks, followed by maintenance use.

Procedural Instructions for Application

The product's efficacy is dependent on a specific contact time during application. The official procedure mandates that the preparation, once applied to wet hair or skin and lathered, must be reapplied and allowed to remain on the affected area for a minimum duration of three minutes before the final rinse. This contact time is critical to the standardized administration protocol. Usage instructions also include the strict procedural constraint to avoid contact with the eyes during application; any accidental contact requires thorough rinsing with water.

This structured, time-specific protocol defines the standardized method for the product’s use, ensuring adherence to the intended administration pattern detailed in documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kelual DS

Evidence for Use in Seborrheic Dermatitis of the Scalp

Research for Kelual DS has explored symptom patterns and changes in the context of Seborrheic Dermatitis (SD) of the scalp. The research landscape includes Randomized Controlled Trials (RCTs), often comparing the product to a non-active formulation (vehicle-controlled trials), alongside open-label clinical studies. These populations were evaluated in studies focusing on mild to moderate forms of the condition.

The research describes how symptoms evolved in the observed populations during periods of increased symptom activity. Findings describe patterns observed in the studies. The evidence contributes to the broader evidence landscape by reflecting the measured clinical outcomes within the observed time intervals.

Study Outcomes and Symptom Measurement

Studies explored outcomes linked to inflammatory or irritative states. Researchers mainly monitored the intensity of clinical signs and patient-reported outcomes describing perceived discomfort.

  • Clinical Signs: Research examined outcomes related to physical discomfort by measuring changes in investigator-graded scores for scaling severity and the intensity of erythema (redness). These measurements were used in studies to describe the visible signs of the condition.
  • Subjective Outcomes: Patient-reported outcomes (PROs) describing perceived discomfort, such as the severity and frequency of pruritus (itching), were evaluated in study subjects.
  • Microbiological Factors: Research has examined changes in microbiological markers, with data showing patterns related to levels of Malassezia species on the scalp surface, used in research exploring how symptoms change over time in trials assessing short-term or episodic symptom patterns.

Long-Term Follow-up and Recurrence Studies

Research monitored how symptoms evolved in the observed populations over defined time intervals to assess recurrence rates in studies observing responses over defined time intervals. Evidence remains limited regarding the long-term effects of the combination product. The available data from these studies contribute to understanding symptom patterns during and immediately following periods of heightened symptom activity. However, evidence provides context but not individual predictions, and long-term effects are not fully established.

Evidence Gaps and Areas of Uncertainty

A major limitation of the current research is the follow-up duration. Findings describe group patterns, not personal outcomes, and the majority of research has focused on the initial intensive phase or short-term maintenance, so long-term effects are not fully established for a chronic, recurring condition. Data for certain groups, such as children or pregnant populations, remain insufficient. The research provides context but not individual predictions, and research does not determine whether an individual will respond similarly regarding the consistent management of the condition.

Key Studies & References

  1. Ciclopirox Shampoo, 1% Label (NIH DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Kelual DS (FAQ)

Q: Can Kelual DS be used on areas of the body other than the scalp, such as the face or chest?

Topical products containing the active ingredients in Kelual DS are typically indicated for use on the scalp for seborrheic dermatitis. In other formulations, they are used on various affected and surrounding skin areas of the body for other fungal conditions. Official product information suggests that use on areas like the face or chest should be determined in consultation with a healthcare provider.

Q: How often should I use the product during the initial treatment phase?

The recommended pattern of use for the initial treatment phase is described in the official product information for its core active component as typically involving application two times per week for up to four weeks. These application guidelines are based on clinical studies designed to assess initial symptom control.

Q: What does the term 'fungistatic' mean in the context of this product?

Fungistatic describes a mechanism of action where the product works to inhibit the growth and reproduction of fungi, such as Malassezia yeast. Instead of killing the yeast directly, fungistatic agents are designed to control the fungal population, which is one part of the mechanism intended to address symptoms like scaling and flaking.

Q: Are there any warnings about using Kelual DS during pregnancy or while breastfeeding?

Regulatory documents indicate that it is not fully known if the active ingredients in this topical preparation will harm an unborn baby or if they pass into breast milk. Therefore, it is recommended that individuals who are pregnant, plan to become pregnant, or are breastfeeding consult with a healthcare professional before using the product.

Q: Is Kelual DS available over-the-counter or does it require a prescription?

The regulatory status of products containing the primary active ingredient, Ciclopirox 1%, varies by country and formulation. In some regions, Ciclopirox Shampoo 1% is designated as a prescription-only medicine, while other forms or concentrations may be available without one. This is determined by the specific national regulatory authority.

Q: What should I do if the product accidentally gets into my eyes?

Official patient counseling information states that this type of topical product is not intended for use in the eyes. If accidental contact occurs, the eyes should be immediately and thoroughly rinsed with water.

Q: What happens if I forget a dose of the Kelual DS treatment?

Official information regarding a missed application suggests that the product may be used as soon as it is remembered. However, if it is almost time for the next scheduled application, the recommendation is to skip the missed dose and return to the regular routine. The product label recommends against doubling the dose to compensate for a missed application.

How should Kelual DS be stored and disposed of?

Storage and Disposal Information

Official regulatory documents from major government health authorities (such as the EMA, FDA, and Health Canada) do not publicly classify Kelual DS as a prescription or over-the-counter drug requiring a public Summary of Product Characteristics (SmPC) or official Prescribing Information document.

As a specialized dermatological product, the general storage guidelines for this formulation typically align with those for similar cosmetic or personal care preparations. Explicit temperature, light protection, and in-use stability requirements are not documented in public government drug monographs.

Storage Component Official Regulatory Status
Storage Conditions Not specified in public drug regulatory documents.
Child Protection Not specified in public drug regulatory documents.
Disposal Instructions Not specified in public drug regulatory documents.

Regulatory documents do not publicly define how this product must be stored, protected, handled, or disposed of. Consumers should reference the container's label for specific instructions, which often include storing in a cool, dry place and keeping it out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Kelual DS found in:

A-Z Index: